Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-07-03T10:51:35.391Z Has data issue: false hasContentIssue false

53 - Hypercalcemia of malignancy

Published online by Cambridge University Press:  04 August 2010

Paul W. Walker
Affiliation:
U.T. M.D. Anderson Cancer Center, Houston, USA
Michael J. Fisch
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Eduardo Bruera
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Get access

Summary

Introduction

Hypercalcemia of malignancy and tumor-induced hypercalcemia are the two terms used to describe this common and life-threatening complication of cancer. This paraneoplastic syndrome produces a metabolic emergency. It occurs in 10–20% of patients with cancer.

Etiology

A common misconception of the student is that metastases to bone is required to produce hypercalcemia. Although this “local osteolytic hypercalcemia” does occur, particularly in breast cancer and multiple myeloma, a more important cause overall is that termed “humoral hypercalcemia of malignancy.” This is the paraneoplastic process where humoral and paracrine factors produced by tumor cells stimulate osteoclast activity and proliferation resulting in bone resorption, liberating calcium into the circulation. Even in situations of tumor involving bone, such as in breast cancer and multiple myeloma, this humoral process has been demonstrated. Although many substances have been implicated in this role, it is not surprising that the agent deemed most responsible for this syndrome is a protein produced by the cancer that mimics normal parathyroid hormone (PTH). This peptide, termed parathyroid hormone-related protein (PTHrP), shows considerable homology with the natural PTH at the N-terminal, with 8 of the first 13 amino acids being identical. This protein has been found to interact with the PTH receptor with equal affinity to natural PTH. Therefore it has the same effect as PTH, which causes increased bone resorption by osteoclasts and renal calcium reabsorption. The clinician's level of suspicion for hypercalcemia should be raised in cancers where it occurs commonly (Table 53.1).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Body, J J. Current and future directions in medical therapy: hypercalcemia. Cancer 2000;88:3054–83.0.CO;2-Z>CrossRefGoogle ScholarPubMed
Body, J J, Bartl, R, Burckhardt, P. Current use of bisphosphonates in oncology. J Clin Oncol 1998;16:3890–9CrossRefGoogle Scholar
Major, P, Lortholary, A, Hon, J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–67CrossRefGoogle ScholarPubMed
Morton A R, Ritch P S. Hypercalcemia. In Principles and Practice of Supportive Oncology, ed. A Berger, R K Portenoy, D E Weissman, pp. 411–25. Philadelphia: Lippincott-Raven, 1998
Walker, P, Watanabe, S, Lawlor, P, Hanson, J, Pereira, J, Bruera, E. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 1997;8:915–16CrossRefGoogle ScholarPubMed
Warrell R P. Metabolic emergencies: hypercalcemia. In Cancer: Principles and Practices of Oncology, 5th edn, ed. V T Devita Jr, S Hellman, S A Rosenberg, pp. 2486–500. Philadelphia: Lippincott-Raven, 1997

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Hypercalcemia of malignancy
  • Edited by Michael J. Fisch, University of Texas, M. D. Anderson Cancer Center, Eduardo Bruera, University of Texas, M. D. Anderson Cancer Center
  • Book: Handbook of Advanced Cancer Care
  • Online publication: 04 August 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511527081.054
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Hypercalcemia of malignancy
  • Edited by Michael J. Fisch, University of Texas, M. D. Anderson Cancer Center, Eduardo Bruera, University of Texas, M. D. Anderson Cancer Center
  • Book: Handbook of Advanced Cancer Care
  • Online publication: 04 August 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511527081.054
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Hypercalcemia of malignancy
  • Edited by Michael J. Fisch, University of Texas, M. D. Anderson Cancer Center, Eduardo Bruera, University of Texas, M. D. Anderson Cancer Center
  • Book: Handbook of Advanced Cancer Care
  • Online publication: 04 August 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511527081.054
Available formats
×